On Demand Webinar

Tackling Cancer Drug Resistance with CDX Models

To outpace cancer’s resilience, researchers need reliable preclinical models that replicate these resistance pathways. This expert led tech talk highlights how Crown Bioscience develops drug resistant cell line derived xenograft (CDX) models, offering a powerful platform to study mechanisms of resistance and accelerate next-generation therapeutic development.

Watch a preview:

What You’ll Learn:

The challenge of resistance: Explore why drug resistance is a critical barrier and how it arises in cancer treatment.
Mechanistic insights: Understand the genetic, molecular, and microenvironmental drivers of resistance.
Crown Bioscience’s models: Get an overview of our advanced drug-resistant CDX models and how they can be applied in your research.
Real-world examples: Review case studies including resistance to EGFR inhibitors, KRAS G12C, inhibitors, and ADC therapies.
Practical applications: Learn how drug resistant models can inform biomarker discovery, combination strategies, and therapeutic design.

About the Presenter:

Aaron Hua, PhD, Senior Scientist, Cancer Pharm, Crown Bioscience

Dr. Hua is a highly trained cancer biologist with expertise in preclinical cancer therapeutics, immuno-oncology and tumor metastasis. He obtained his PhD from Jilin University, China and completed postdoctoral research at The Jackson Laboratory in the United States. His research includes pioneering studies on allogeneic NK cell transplantation for treating breast cancer, melanoma, and glioma, as well as investigating the potential mechanisms underlying breast cancer lung metastasis.

In 2020, he joined Crown Bioscience, where he currently serves as a Senior Scientist in the Cancer Pharmacology department. Dr. Hua is primarily responsible for the development of syngeneic, CDX, imaging and drug-resistant mouse models to address market needs. Additionally, he supervises cell support department, which mainly focuses on providing tumor cells for in vivo model establishment.

Throughout his career, he has collaborated with numerous renowned pharmaceutical companies, including Johnson & Johnson (J&J) Global, Abbvie, and Beigene, assisting clients in successfully completing over 100 in vivo tumor efficacy evaluation projects. To date, Dr. Hua has co-authored 15 academic papers, including first-author publications, and presented 6 abstracts at prestigious conferences such as American Association for Cancer Research (AACR) and the EORTC-NCI-AACR Symposium (ENA).